The inflammatory disease therapy developer emerged from stealth to commercialise research from several Max Planck institutes and LDC.
Quench Bio, a US-based inflammatory disease drug developer spun out of Max Planck Society and Lead Discovery Center, launched yesterday with $50m of series A funding led by investment management firm RA Capital Management.
AbbVie Ventures, the corporate venturing subsidiary of pharmaceutical firm AbbVie, also took part, as did venture capital firms Atlas Venture and Arix Bioscience. The company was incubated and seeded by Atlas Venture in 2018.
Quench is developing treatments for serious inflammatory diseases that will…
